Specifically IL-17 response to Con-A and irrediated tumor cells were higher in CD200fc treatment group at earlier stage of the disease (12 days after injection of tumor cells) but lower at the final stage of the carcinoma (25 days after injection of tumor cells). This evidence concerns the gene IL17A and carcinoma.